References
- Yarmush ML, Golberg A, Serša G, Kotnik T, Miklavčič D. Electroporationbased technologies for medicine: principles, applications, and challenges. Annu Rev Biomed Eng 2014; 16: 295-320. 10.1146/annurev-bioeng-071813-104622
- Hribernik A, Cemazar M, Sersa G, Bosnjak M, Snoj M. Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patients. Radiol Oncol 2016; 50: 21-7. 10.1515/raon-2015-0048
- Campana LG, Clover AJ, Valpione S, Quaglino P, Gehl J, Kunte C, et al. Recommendations for improving the quality of reporting clinical electro-chemotherapy studies based on qualitative systematic review. Radiol Oncol 2016; 50: 1-13. 10.1515/raon-2016-0006
- Cemazar M, Golzio M, Sersa G, Rols MP, Teissié J. Electrically-assisted nucleic acids delivery to tissues in vivo: where do we stand? Curr Pharm Des 2006; 12: 3817-25. 10.2174/138161206778559740
- Heller R, Heller LC. Gene electrotransfer clinical trials. Adv Genet 2015; 89: 235-62. 10.1016/bs.adgen.2014.10.006
- Heller LC, Heller R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr Gene Ther 2010; 10: 312-7. 10.2174/156652310791823489
- Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26: 5896-903. 10.1200/JCO.2007.15.6794
- Spanggaard I, Snoj M, Cavalcanti A, Bouquet C, Sersa G, Robert C, et al. Gene electrotransfer of plasmid antiangiogenic metargidin peptide (AMEP) in disseminated melanoma: safety and efficacy results of a phase I first-in-man study. Hum Gene Ther Clin Dev 2013; 24: 99-107. 10.1089/humc.2012.240
- Heller L, Todorovic V, Cemazar M. Electrotransfer of single-stranded or double-stranded DNA induces complete regression of palpable B16.F10 mouse melanomas. Cancer Gene Ther 2013; 20: 695-700. 10.1038/cgt.2013.71
- Znidar K, Bosnjak M, Cemazar M, Heller LC. Cytosolic DNA sensor upregulation accompanies DNA electrotransfer in B16.F10 melanoma cells. Mol Ther Nucleic Acids 2016; 5 : e322. 10.1038/mtna.2016.34
- Desmet CJ, Ishii KJ. Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination. Nat Rev Immunol 2012; 12: 479-91. 10.1038/nri3247
- Baskar R, Ann-Lee K, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. Int J Med Sci 2012; 9: 193-9. 10.7150/ijms.3635
- Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 2015; 1: 1-8. 10.1001/jamaoncol.2015.2756
- Deng L, Liang H, Xu M, Yang X, Burnette B, Arina A, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014; 41: 543-52. 10.1016/j.immuni.2014.10.019
- Deng L, Liang H, Fu S, R.weichselbaum R, Fu YX. From DNA damage to nucleic acid sensing: A strategy to enhance radiation therapy. Clin Cancer Res 2016; 22: 20-5. 10.1158/1078-0432.CCR-14-3110
- El Kaffas A, Tran W, Czarnota GJ. Vascular strategies for enhancing tumour response to radiation therapy. Technol Cancer Res Treat 2012; 11: 421-32. 10.7785/tcrt.2012.500265
- Sedlar A, Kranjc S, Dolinsek T, Cemazar M, Coer A, Sersa G. Radiosensitizing effect of intratumoral interleukin-12 gene electrotransfer in murine sarcoma. BMC cancer 2013; 13: 38. 10.1186/1471-2407-13-38
- Stimac M, Kamensek U, Cemazar M, Kranjc S, Coer A, Sersa G. Tumor radio-sensitization by gene therapy against endoglin. Cancer Gene Ther 2016; 23: 214-20. 10.1038/cgt.2016.20
- Dolinsek T, Markelc B, Bosnjak M, Blagus T, Prosen L, Kranjc S, et al. Endoglin silencing has significant antitumor effect on murine mammary adenocarcinoma mediated by vascular targeted effect. Curr Gene Ther 2015; 15: 228 44. 10.2174/156652321566615012611 5501
- Dolinsek T, Markelc B, Sersa G, Coer A, Stimac M, Lavrencak J, et al. Multiple delivery of siRNA against endoglin into murine mammary adenocarcinoma prevents angiogenesis and delays tumor growth. PLoS One 2013; 8: e58723. 10.1371/journal.pone.0058723
- Stimac M, Dolinsek T, Lampreht U, Cemazar M, Sersa G. Gene electrotransfer of plasmid with tissue specific promoter encoding shRNA against endoglin exerts antitumor efficacy against murine TS/A tumors by vascular targeted effects. PLoS One 2015; 10: e0124913. 10.1371/journal. pone.0124913
- Tesic N, Kamensek U, Sersa G, Kranjc S, Stimac M, Lampreht U, et al. Endoglin (CD105) Silencing mediated by shrna under the control of endothelin-1 promoter for targeted gene therapy of melanoma. Mol Ther Nucleic Acids 2015; 4: e239. 10.1038/mtna.2015.12
- Dolinsek T, Sersa G, Prosen L, Bosnjak M, Stimac M, Razborsek U, et al. Electrotransfer of plasmid DNA encoding an anti-mouse endoglin (CD105) shRNA to B16 melanoma tumors with low and high metastatic potential results in pronounced anti-tumor effects. Cancers 2015; 8: 3. 10.3390/ cancers8010003
- Papadakis ED, Nicklin S a, Baker a H, White SJ. Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther 2004; 4: 89-113. 10.2174/1566523044578077
- Bosnjak M, Dolinsek T, Cemazar M, Kranjc S, Blagus T, Markelc B, et al. Gene electrotransfer of plasmid AMEP, an integrin-targeted therapy, has antitumor and antiangiogenic action in murine B16 melanoma. Gene Ther 2015; 22: 578-90. 10.1038/gt.2015.26
- Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24: 148-54. 10.1007/BF00300234
- Kamensek U, Tesic N, Sersa G, Kos S, Cemazar M. Tailor-made fibroblast-specific and antibiotic-free interleukin 12 plasmid for gene electrotransfermediated cancer immunotherapy. Plasmid 2016; 89: 9-15. 10.1016/j. plasmid.2016.11.004
- Dempsey A, Bowie AG. Innate immune recognition of DNA: A recent history. Virology. 2015; 479: 146-52. 10.1016/j.virol.2015.03.013
- Chiarella P, Fazio VM, Signori E. Electroporation in DNA vaccination protocols against cancer. CurrDrug Metab 2013; 14: 291-9. org/10.2174/156652310791823506
- Muralidharan S, Mandrekar P. Cellular stress response and innate immune signaling: integrating pathways in host defense and inflammation. J Leukoc Biol 2013; 94: 1167-84. 10.1189/jlb.0313153
- Tarek M. Membrane electroporation: A molecular dynamics simulation. Biophys J 2005; 88: 4045-53. 10.1529/biophysj.104.050617
- Markelc B, Tevz G, Cemazar M, Kranjc S, Lavrencak J, Zegura B, et al. Muscle gene electrotransfer is increased by the antioxidant tempol in mice. Gene Ther 2012; 19: 312-20. 10.1038/gt.2011.97
- Bolus NE. Basic review of radiation biology and terminology. J Nucl Med Technol 2001; 29: 67-73.
- Watters D. Molecular mechanisms of ionizing radiation-induced apoptosis. Immunol Cell Biol 1999; 77: 263-71. 10.1046/j.1440-1711.1999.00824.x
- Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300: 1155-9. 10.1126/science.1082504
- Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005; 174: 7516-23. 10.4049/jimmunol.174.12.7516
- Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 2009; 114: 589-95. 10.1182/ blood-2009-02-206870
- Sersa G, Kranjc S, Cemažar M. Improvement of combined modality therapy with cisplatin and radiation using electroporation of tumors. Int J Radiat Oncol Biol Phys 2000; 46: 1037-41. 10.1016/S0360-3016(99)00464-2
- Bonnafous P, Vernhes MC, Teissié J, Gabriel B. The generation of reactive-oxygen species associated with long-lasting pulse-induced electropermeabilisation of mammalian cells is based on a non-destructive alteration of the plasma membrane. Biochim Biophys Acta 1999; 1461: 123-34. 10.1016/S0005-2736(99)00154-6
- Maio M. Melanoma as a model tumour for immuno-oncology. Ann Oncol 2012; 23: 10-4. 10.1093/annonc/mds257
- Ratterman M, Hallmeyer S, Richards J. Sequencing of new and old therapies for metastatic melanoma. Curr Treat Options Oncol 2016; 17: 1-9. 10.1007/s11864-016-0427-z
- Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer 2012; 12: 307-13. 10.1038/nrc3246